AbCellera Biologics Inc.
ABCL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -47.6% | 303.4% | -16.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 58.7% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -449.2% | -227.3% | -1,225.5% | -1,095.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -637.8% | -203.3% | -1,077.2% | -677.4% |
| EPS Diluted | -0.19 | -0.12 | -0.15 | -0.12 |
| % Growth | -58.3% | 20% | -25% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |